Analysis

Will Big Drugmakers Mimic Purdue On Opioid Marketing?

Law360 (February 12, 2018, 9:50 PM EST) -- Purdue Pharma's decision to scale back its opioid marketing amid an onslaught of litigation will force many big drugmakers to consider similar moves, potentially marking a seminal moment in the nation's brutal opioid epidemic.

Purdue announced over the weekend that it cut its sales force in half and stopped sending opioid promoters to physician offices "effective immediately." The decision comes as Purdue and other opioid sellers are embroiled in multidistrict litigation in Ohio federal court, where U.S. District Judge Dan Polster is hoping for a quick settlement that would sharply cut the number of narcotic painkillers in circulation.

Experts say that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!